Abstract
Recent developments in our knowledge of the renin-angiotensin system (RAS) necessitate an update of the classical view on this system. These developments pertain to the pathways leading to formation of angiotensin II and other active metabolites, their receptors, biological functions and the presence of renin-angiotensin systems in tissues. The implications of the above new developments for the current interest in tissue renin-angiotensin systems as potential targets for drug therapy in cardiovascular disease are discussed in this review.
MeSH terms
-
Angiotensin II / biosynthesis
-
Angiotensin-Converting Enzyme Inhibitors / chemistry
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
-
Animals
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / metabolism
-
Gene Expression Regulation, Enzymologic / drug effects
-
Humans
-
Peptidyl-Dipeptidase A / genetics
-
Polymorphism, Genetic / drug effects
-
Receptors, Angiotensin / chemistry
-
Receptors, Angiotensin / physiology
-
Renin-Angiotensin System / drug effects*
-
Renin-Angiotensin System / physiology
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Receptors, Angiotensin
-
Angiotensin II
-
Peptidyl-Dipeptidase A